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The laboratory diagnosis of Pneumocystis pneumonia, referred to as PcP, and caused 48 by the opportunistic fungal pathogen Pneumocystis jirovecii, still relies on tinctorial and/or 49 immunofluorescent staining of bronchoalveolar lavage (BAL) fluid samples (27) . In contrast 50 to microscopy, nucleic acid amplification tests can overcome the difficulties of microscopic 51 examination (27). Several previously reported PCR studies have used nested PCR with a final 52 endpoint reading (16, 20) . This format is not intended to give quantitative results and is prone 53 to contamination with previously amplified products leading to false positive results. In 54 contrast, real time quantitative PCR (qPCR) dramatically reduces the risk of false positive 55 because of the close-tube nature of the amplification process (6) and the resulting data are 56 quantitative if guidelines for interpretation qPCR results are followed (7). 57
Several qPCR assays have already been published and have shown that qPCR is 58 more sensitive than microscopy (1-3, 5, 10-12, 14, 15, 17, 18, 22, 26). This raises the issue 59 of the clinical significance of P. jirovecii DNA detection for explaining the symptoms 60 observed (24, 25). Quantitative PCR data can also address the issue of the correlation 61 between tissue burden and outcome (16). In particular, we questioned the use of 62 microscopically detectable P. jirovecii cysts as a threshold for therapeutic decision making, 63 especially if extended to all patients whatever their risk factors for developing PcP. 64
Therefore, we developed a qPCR assay and tested all the bronchoalveolar lavage (BAL) 65 fluids received by our laboratory without selection of the patients from whom samples were 66 (UDG) (Biolabs, Courtaboeuf, France). The reaction mixture was initially incubated for 1 min 110 at 50°C followed by a 8-min step at 95°C. Amplification was performed for 50 cycles of 111 denaturation (95°C for 10 s; ramp rate, 20°C/s), annealing (60°C for 10 s; ramp rate, 20°C/s), 112 and extension (72°C for 15 s; ramp rate, 20°C/s). Results were considered as positive when a 113 significant fluorescent signal above the base-line was detected as determined by the second-114 derivative algorithm method and were expressed as quantification cycle (Cq) values. During 115 each run, a P. jirovecii DNA positive control and the elution buffer for DNA extraction as a 116 negative control were used. Residual amplification inhibitory effect in the DNA extract was 117 tested by using a universal internal standard as previously described (8) could interfere with qPCR quantification, we checked that it did not significantly differ 160 between the three groups (Table 2, p>0.05). The copy number was markedly (more than three 161 logs in magnitude) higher for IFA-positive/qPCR-positive samples than for IFA-162 negative/qPCR-positive samples (4.2±1.2 vs. 1.1±1.1 log10 copies/µl, p<10 -4 ) ( Table 2 ). With 163 IFA as the standard, the qPCR assay sensitivity was found to be 100% for samples containing 164 ≥2.6 log10 copies/µl and the specificity was 100% for those with ≥ 4.0 log10 copies/µl. 165
Among the 13 samples containing ≥2.6 log10 and <4.0 log10 copies/µl, 8 were IFA-166 negative/qPCR-positive. These 8 samples were from 8 patients who were not given co-167 trimoxazole and 5 of them died at day 6 (solid cancer), day 120 (HIV-positive patient), day 168 197 (acute myeloid leukemia), day 289 (acute lymphoid leukemia) and day 353 (HIV-positive 169 patient) from the day of the first BAL. 170
The presence of diffuse pulmonary lesions with no localized/focal lesions on chest X-171 ray or CT-scan imaging was unequally distributed among the three groups (Table 2) . 172
However, although there were more diffuse lesions in the IFA-negative/qPCR-positive group 173 than in the IFA-negative/qPCR-negative one, the difference was not statistically significant 174 (p=0.24). In contrast, the difference in anti-PcP prophylaxis at the time of the BAL was 175 highly significant with almost no prophylaxis in patients with qPCR-positive samples (Table  176 on (Table  187 3). The 19 IFA-negative/qPCR-negative samples recovered from patients with CD4+ T cell 188 count < 200 cells/µl, 15 (78.9%) corresponded to patients under anti-PcP prophylaxis. 189
Among the 147 samples from the hematological population, only 6 (4.1%) were IFA-190 positive/qPCR-positive whereas 24 (16.3%) were IFA-negative/qPCR-positive (Table 3) . is the criterion to define PcP, the sensitivity of our qPCR assay was 100% for samples with 252 ≥2.6 log10 copies/µl and the specificity was 100% for samples with ≥ 4 log10 copies/µl. 253
Thus, for eight IFA-negative patients, a specific therapy was not started although they had 254 on November 13, 2017 by guest http://jcm.asm.org/ Downloaded from 11 positive qPCR results between our thresholds of sensitivity and specificity. This suggests that 255 IFA positivity cannot be the sole criterion to start specific therapy. Imaging cannot help in the 256 IFA-negative/qPCR-positive cases since the lung lesions observed were not different from 257 those seen in the IFA-negative/qPCR-negative group. Also, a strategy based mainly on 258 clinical and radiological signs does not take into account the fungal load which is yet an 259 important issue in other infectious diseases. In hematology for instance, the treatment of 260 CMV disease is started above a consensual threshold (19), and for infection with Toxoplasma 261 gondii, the recommendation is to start therapy as soon as a blood PCR result is positive (21). 
